semaglutide common name Tablets Semaglutide | C187H291N45O59 | CID

[10,11] In a real-world cohort transitioning off GLP-1 RA therapy to cost-effective medications with weight-lowering effects, metformin was the most frequently utilized agent as maintenance treatment in about 80% patients

Targeted medicines with few adverse effects may become a reality once these pathways are understood

Coverage options for GLP-1 medications expanded significantly in 2026

doi:10.3390/diagnostics13203172

Loss objectives, particularly when combined with exercise

Executive Summary Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of obesity and type 2 diabetes